VIVS (Organovo Holdings, Inc.) Return on Gross Profit

Corporate emblem and logo of Organovo Holdings (VIVS)

VivoSim Labs Inc (VIVS) consistently operates its tissue bioprinting capacities, eliminating equipment downtime. Business efficiency is based on the precision of 3D models during drug testing, as confirmed by the GURU.Markets terminal linear chart for gross margin as a percentage of revenue, where the indicator reached -67.40. The development strategy relies on creating organs for transplantation, reducing research costs for pharma behemoths.

organovo.com (VIVS) Gross Profitability: for the period 04/25/2025 - 11/20/2026

Financial and market metric breakdowns for Organovo (VIVS)

- current quotes and average value forecast:
- business market valuation indicators:
Basic company analysis:VIVS (Organovo Holdings)
Manufactured products of organovo.com

To select fundamentally strong assets, it is essential for an investor to evaluate production efficiency through operating profitability. Gross margin measures the portion of revenue remaining after deducting direct product creation costs, reflecting the business's pricing power. For VivoSim Labs Inc (VIVS), with its unique bioprinting patents, this metric confirms the high value of its technologies, as clearly demonstrated by the gross profit margin.